GlassScriptPhysician profile
Robert G Browning
NPI 1073585824
$2,694.16
in general payments reported to CMS, 2019-2025
26 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $261 · 2021: $384 · 2022: $354 · 2023: $432 · 2024: $511 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.69 | 2020-2025 | Synthroid, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $362.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $276.79 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $217.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $208.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Alcon Vision LLC | $183.29 | 2024-2025 | Rocklatan, Clareon |
| Otsuka America Pharmaceutical, INC. | $156.66 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $130.65 | 2021-2024 | Verquvo, Gardasil, Gardasil 9 |
| Amgen INC. | $86.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $76.34 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.69 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $47.20 | 2024 | Voquezna |
| Medtronic, INC. | $41.93 | 2023-2024 | Intellis Adaptivestim |
| Astellas Pharma US INC | $41.22 | 2019-2023 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.76 | 2022-2023 | Xifaxan |
| Genentech USA, INC. | $28.08 | 2020-2021 | |
| Boston Scientific Corporation | $26.19 | 2021 | |
| Avion Pharmaceuticals | $23.98 | 2020 | |
| Dexcom, INC. | $22.83 | 2021 | |
| Becton, Dickinson and Company | $18.07 | 2019 | |
| Averitas Pharma INC. | $17.64 | 2025 | Qutenza |
| Sumitomo Pharma America, INC. | $17.01 | 2023 | Gemtesa |
| Inari Medical, INC. | $14.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bausch & Lomb Americas INC. | $13.97 | 2024 | Vyzulta, Miebo |
| Allergan, INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.